Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ELANE | P08246 | 13/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603908 | 0.93 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| Tolnidamine SCHEMBL1604178 | 0.85 | CYP1A2 (0.78) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL3408437 | 0.84 | CYP1A2 (0.72) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL30491087 | 0.84 | CYP1A2 (0.72) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL14595157 | 0.83 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL14584215 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL12787802 | 0.80 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL14584198 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL998543 | 0.79 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL29459648 | 0.79 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | CYP1A2 4551/4885CYP3A4 4009/4885CYP2D6 4125/4885 |
| US-20070043057-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | CYP1A2 4551/4885CYP3A4 4009/4885CYP2D6 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.